EUVIMEDEUVIMED entdecken
Open Access

GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment

Rami A Ballout, Alan T Remaley

Journal of Laboratory and Precision Medicine · 2020-04 · 5 · 17-17

DOI: 10.21037/jlpm.2020.03.03 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Laboratory and Precision Medicine, 2020-04. Verfasst von Rami A Ballout und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lipoprotein Metabolism Section, Translational and Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of …. Die Arbeit wurde bisher 85-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The GlycA test is a recently developed proton nuclear magnetic resonance (1H-NMR) spectroscopy-based assay that has been gaining increased interest as a serum biomarker for systemic inflammation, and consequently, as a potential biomarker for cardiovascular disease (CVD) risk assessment. The test has undergone investigation in several large cohort studies, since its development, to assess its predictive value for incident CVD events, CVD-associated mortality, and all-cause mortality. Despite variation in the generated estimates by these studies, they have all consistently demonstrated moderate-strength positive correlations between baseline GlycA levels, and incident CVD event rates and associated mortality. These correlations withheld testing even after adjusting for several other established CVD risk factors, including notable inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). Compared with hsCRP, which is a well-known inflammatory biomarker for CVD risk assessment, GlycA has a comparable predictive value for future CVD-related events. However, the indications to pursue GlycA testing, and its clinical utility in patient care management, are yet to be determined. In this review, we define the GlycA test and what it "measures", and provide a brief summary of the findings of studies showing its association with incident CVD rates, and CVD-related mortality, as well as its correlation with other inflammatory biomarkers, namely hsCRP. Finally, we highlight the analytical advantages of the GlycA test, compared with "traditional" inflammatory biomarkers, while also mentioning its current limitations.

Schlagwörter

Stichwörter der Autor:innen

GlycAN-glycansacute phase reactantsatherosclerosiscoronary artery diseasehsCRP

Autor:innen und Institutionen

  • Lipoprotein Metabolism Section, Translational and Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD, USA.

Förderung

  • Intramural NIH HHS

Zitieren

APA

Ballout, R. A., & Remaley, A. T. (2020). GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. Journal of Laboratory and Precision Medicine, 5, 17-17. https://doi.org/10.21037/jlpm.2020.03.03

Vancouver

Ballout RA, Remaley AT. GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. Journal of Laboratory and Precision Medicine. 2020;5:17-17. doi:10.21037/jlpm.2020.03.03

BibTeX
@article{Ballout2020,
  author = {Ballout, Rami A and Remaley, Alan T},
  title = {GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment},
  journal = {Journal of Laboratory and Precision Medicine},
  year = {2020},
  volume = {5},
  pages = {17--17},
  doi = {10.21037/jlpm.2020.03.03}
}
Kostenlos starten →